Deals in Depth: June/July 2010
Executive Summary
Front-runners for June alliances were J&J's $586 million respiratory deal with Orexo and Bayer Schering's cancer partnership with OncoMed valued at about $540 million. Leading the pack for biopharma M&A was Grifol's $3.4 billion bid (plus $600 million in debt) for privately owned Talecris. In financings, both biopharma and device companies were busy raising private money, bringing in over $1.3 billion in June and July (compared with only $157 million in public sales).